Anzeige
Mehr »
Montag, 18.08.2025 - Börsentäglich über 12.000 News
6,35-Mrd. vs. 30-Mio.-€ - Die Bewertungslücke im Kohlesektor, die kein Investor ignorieren kann
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCUH | ISIN: SE0014855029 | Ticker-Symbol: 8IM1
Tradegate
15.08.25 | 16:28
6,430 Euro
-1,38 % -0,090
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMPLANTICA AG SDR Chart 1 Jahr
5-Tage-Chart
IMPLANTICA AG SDR 5-Tage-Chart
RealtimeGeldBriefZeit
6,9007,00014:21
6,9007,00014:15

Aktuelle News zur IMPLANTICA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoImplantica publishes Interim Report January - June 2025 (Q2)266VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA...
► Artikel lesen
MiImplantica finishes new multi-cavity production tool for RefluxStop to support manufacturing ramp-up in the U.S. pending FDA approval266VADUZ, Liechtenstein, Aug. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop®...
► Artikel lesen
07.08.Implantica presents the second quarter 2025 on August 14 at 15:00 CEST175VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the second quarter 2025 at 15:00 CEST on August 14. The interim report for the...
► Artikel lesen
07.08.Implantica announces second publication of groundbreaking 5-year results from the landmark RefluxStop clinical study237VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed...
► Artikel lesen
IMPLANTICA Aktie jetzt für 0€ handeln
01.07.Implantica announces publication of the landmark RefluxStop 5-year clinical study results demonstrating excellent long-term success303VADUZ, Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device RefluxStop®, a treatment field...
► Artikel lesen
24.06.Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop for US market approval377VADUZ, Liechtenstein, June 24, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
17.06.Implantica announces successful UK RefluxStop Users Meeting addressing growing demand after the final and positive UK NICE recommendations on use of RefluxStop in NHS public hospitals288VADUZ, Liechtenstein, June 17, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of treatment for acid reflux with its unique device RefluxStop, a treatment field...
► Artikel lesen
12.06.Implantica announces new real-world Swiss study on 99 RefluxStop patients comparing small and large hiatal hernia, confirming equally excellent long-term results264VADUZ, Liechtenstein, June 12, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
04.06.Implantica announces that UK NICE has published positive recommendations for the RefluxStop procedure in the NHS public hospitals338VADUZ, Liechtenstein, June 4, 2025 /PRNewswire/ -- Implantica AG (publ.), providing the unique device RefluxStop for the treatment of acid reflux, announces that the world-renowned National...
► Artikel lesen
27.05.Implantica's RefluxStop stimulates intensive dialogue at DDW, the world's largest Digestive Disease conference, held in the U.S.493VADUZ, Liechtenstein, May 27, 2025 /PRNewswire/ -- Implantica AG (publ.) reports successful pre-launch activities in the U.S., pending FDA approval, with European real-world clinical evidence...
► Artikel lesen
15.05.Bulletin from the Annual General Meeting of Implantica AG357VADUZ, Liechtenstein, May 15, 2025 /PRNewswire/ -- Today, May 15, 2025, the annual general meeting (the "AGM") of Implantica AG (publ) was held in Ruggell, Liechtenstein. The general meeting...
► Artikel lesen
09.05.Implantica publishes Interim Report January - March 2025 (Q1)396VADUZ, Liechtenstein, May 9, 2025 /PRNewswire/ -- Global expansion of RefluxStop Significant events in the first quarter of 2025 Received positive feedback from U.S. FDA on...
► Artikel lesen
06.05.Implantica announces 15th RefluxStop Center in Spain318VADUZ, Liechtenstein, May 6, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop...
► Artikel lesen
02.05.Implantica presents the first quarter 2025 on May 9 at 15:00 CEST335VADUZ, Liechtenstein, May 2, 2025 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the first quarter 2025 at 15:00 CEST on May 9. The interim report for the first...
► Artikel lesen
25.04.Notice of Annual General Meeting of Implantica AG505VADUZ, Liechtenstein, April 25, 2025 /PRNewswire/ -- The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to...
► Artikel lesen
23.04.Implantica opens a new RefluxStop center in a new region of Spain, addressing the fast-growing demand318VADUZ, Liechtenstein, April 23, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
15.04.Implantica publishes Annual Report 2024346VADUZ, Liechtenstein, April 15, 2025 /PRNewswire/ -- Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report...
► Artikel lesen
10.04.Implantica announces a newly published real-world study from Germany reinforcing the excellent RefluxStop results465VADUZ, Liechtenstein, April 10, 2025 /PRNewswire/ -- Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
25.03.Implantica's RefluxStop garners strong interest at SAGES409VADUZ, Liechtenstein, March 25, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
19.03.Implantica announces further expansion of RefluxStop centers of excellence and patient access in Spain447VADUZ, Liechtenstein, March 19, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1